Pentosan Polysulfate
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Semi-synthetic glycosaminoglycan for joint cartilage and interstitial cystitis.
Reported benefits
Joint protection, cartilage health, anti-inflammatory, bladder health
Protocols & dosing
Typical dosage: 300 mg (daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Pentosan Polysulfate is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Possible GI upset, hair loss (rare)
References
No external sources have been catalogued for this article yet.
Related peptides
- Actovegin — Tissue regeneration complex
- BPC-157 — Healing & recovery, gut health
- BPC-157 Stable — Stabilized BPC variant
- FGL (Fibroblast Growth-Like) — Neural repair peptide
- GHK-Cu — Wound healing, skin regeneration
- Ghrelinomimetic — Appetite and healing support
Categories: Healing & Recovery